$FRNM

Freenome, Inc. (FRNM): Completion of Acquisition or Disposition of Assets

Freenome, Inc. (FRNM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 19 ef20078324_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the “Form 8-K”) filed with the Sec

Original reporting
Published Jul 24, 2026, 1:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMergers & acquisitions
Primary signal
$FRNM
Bullish
medium confidence
Mentioned
$FRNM
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FRNMBullishMed
01

Why it matters

The key actionable items are the confirmed closing of the reverse recapitalization and the PIPE investment of $240m at $10.00 per share, which can change valuation expectations and trading behavior.

02

Market read

Deal completion plus a large PIPE at a fixed price is a concrete catalyst for valuation and near-term trading positioning.

03

What to watch

Traders should watch for post-close share count dilution, warrant/option exchange mechanics, and any subsequent filings that clarify governance and financial guidance.

Relevance 7/10Novelty 7/10Timing: post-close, filed July 23, 2026 after-hours/overnight

Background

The 8-K is a post-closing update for Freenome, Inc., formerly Perceptive Capital Solutions Corp., describing the completed business combination and related pro forma financial information.

Company-level read

Ticker impact

$FRNMBullishMedium confidence
Context

Freenome’s 8-K says the business combination was completed, including domestication, mergers, and a PIPE purchase of 24,000,000 shares at $10.00.

Expected impact

Likely near-term volatility as the market digests the completed transaction terms and the $240m PIPE proceeds.

Evidence & confidence

The filing confirms closing and provides concrete deal mechanics (exchange ratio and PIPE size/price), which typically affects valuation, share count, and post-close trading dynamics.

Market effects

Limited direct sector read-across; this is primarily a company-specific corporate action affecting biotech/healthtech capital markets positioning.

Primarily US-listed microcap/small-cap liquidity and sentiment impact.

Low global relevance beyond investors tracking the reverse recap and PIPE financing.

Counterpoint

The filing is largely mechanical deal-completion boilerplate, so price may already reflect the transaction and react only modestly.

Key entities

  • Freenome, Inc.

    Subject of the 8-K, which completed the business combination and changed corporate name from PCSC.

  • Perceptive Capital Solutions Corp.

    Pre-closing entity that consummated the business combination and then changed its corporate name to Freenome.

Related articles

$AEMDHighAI 8/10

Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.

$FRNMMed

Jefferies sets strong price target on upstart cancer stock

Jefferies initiated coverage on Freenome (FRNM) with a 'Buy' rating and $17 price target, citing its cancer detection tests and partnerships. Shares rose 12% to $13.00. Freenome's lead product, SimpleScreen, competes in colorectal cancer testing. The company plans to expand into other cancers, with lung cancer next. Key milestones include FDA approvals and a U.S. launch this fall. Freenome is unprofitable but has $1.3B market cap. Jefferies' target implies 47% upside from $11.56 close.

$NEEHighAI 9/10

NextEra-Dominion Merger Wins Shareholder Backing: What’s Next?

NextEra Energy (NEE) and Dominion Energy (D) shareholders approved their merger, creating the world's largest regulated electric utility. The deal aims to capitalize on growing US power demand, particularly from data centers. However, regulatory approvals are still pending, with concerns raised by state governors about potential impacts on consumers and energy costs. The transaction is an all-stock deal, with Dominion shareholders receiving NextEra shares.

$FLEXHighAI 9/10

FLEX Makes a $4.4 Billion Bet on AI Power

Flex Ltd. (FLEX) will acquire EPC Power for $4.4B, expanding its AI data center power infrastructure. The deal, expected to close in Q4 2026, will add EPC Power to Flex's CPI segment. Flex plans to spin off CPI in Q1 2027. EPC Power is projected to generate $800M in 2026 revenue, with 40% growth and 30% EBITDA margin in 2027. Financing will come from debt and equity, with Citi and Bank of America providing committed financing.

$SLBHighAI 9/10

SLB Bets $4.1 Billion on the AI Data Center Boom

SLB NV (NYSE:SLB) will acquire Kelvion for $4.1B, expanding its data center business. The deal aims to double revenue per gigawatt and is expected to be accretive to earnings and free cash flow within 12 months. SLB projects $120M in annual EBITDA synergies within three years and reaffirmed its $4B shareholder return target for the fiscal year.